



VIVALDI BIOSCIENCES ANNOUNCES PRESENTATION AT AMERICAN SOCIETY FOR VIROLOGY VIRTUAL ANNUAL MEETING

FORT COLLINS, Colorado and VIENNA, Austria – June 15, 2020 – Vivaldi Biosciences, a clinical-stage biotechnology company developing the DeltaFLU universal influenza vaccine, today announced that Amy Aspelund, Vice President, Research & Development, is scheduled to present at the Vaccines Virtual Workshop of the 39th Annual Meeting of the American Society for Virology on June 19, 2020. Ms. Aspelund will deliver a presentation on Vivaldi's innovative Vero cell-based vaccine manufacturing system.

The American Society for Virology's 2020 Annual Meeting (ASV 2020), originally scheduled to take place June 13-17 in Fort Collins, CO, was cancelled due to public health concerns regarding the COVID-19 pandemic. ASV 2020 will take place in the form of Virtual Workshops.

Details of the presentation are as follows:

Presenter: Amy Aspelund, Vice President, Research & Development, Vivaldi Biosciences

Date: June 19, 2020

Time: 4:45 pm EDT

Registration: <https://zoom.us/meeting/register/tJ0lfuGpqjsiH9P5Z1fZQBJHT9V-H0IFnwZR>

Presentation Title: Optimization of Vero-cell manufacturing of DeltaFLU universal influenza vaccine

Authors: Amy Aspelund, Melissa Vivian, Alaura Hoag, Markus Wolschek, Manfred Reiter, Boris Ferko and Thomas Muster

About Vivaldi Biosciences

Vivaldi Biosciences is developing its DeltaFLU universal influenza vaccine to provide broad protection and superior efficacy in the prophylaxis of seasonal and pandemic influenza. Administered as a nasal spray, DeltaFLU is composed of influenza vaccine strains genetically modified by deletion of the gene for nonstructural protein 1 (NS1). The NS1 protein blocks interferon, a key component of the immune system's response to viral infection. Lacking NS1, DeltaFLU rapidly induces interferon and broadly neutralizing mucosal antibodies in the nasal passages, creating a first line of defense directly at the point of entry of circulating viruses. The self-adjuvanting effect of interferon also creates a second line of defense by stimulating the immune system's T cells and antibody-producing B cells to achieve a broadly protective systemic immune response. DeltaFLU strains are replication-deficient and are not shed by the recipient, providing significant safety advantages. Four completed clinical studies show DeltaFLU is safe and generates a potent, broad immune response. Nonclinical studies demonstrate the feasibility of universal protection with DeltaFLU, showing protection against challenge with drifted and shifted influenza A and B strains. Vivaldi has established a high-yield Vero cell production system enabling efficient, low-cost production of DeltaFLU. The 7-week production timeline enables rapid response to an influenza pandemic. Vivaldi Biosciences is based at the Research Innovation Center at Colorado State University, Fort Collins, CO and in Vienna, Austria. NGN Capital LLC is the lead investor in Vivaldi Biosciences. Additional information can be found at www.vivaldibiosciences.com.

Contact:

Bill Wick, CEO, Vivaldi Biosciences

Tel: +1 650-400-8915

bill.wick@vivaldibiosciences.com

Forward-Looking Statements

This release contains forward-looking statements relating to Vivaldi Biosciences, which are not historical facts and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this communication concerning activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are based on current expectations and projections about future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, the following: the uncertainty of clinical success and of obtaining regulatory approvals, the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, product efficacy or safety concerns resulting in product recalls or regulatory action, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the ability to obtain future funding and to obtain such funding on commercially reasonable terms, the regulatory environment and other risks the Company may identify from time to time in the future. These factors are not necessarily all of the important factors that could cause our actual results, performance or achievements to differ materially from those expressed in or implied by any of our forward-looking statements. These forward-looking statements speak only as of the date of this communication and we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. This press release should not constitute an offer to sell or a solicitation of an offer to buy securities.